Navigation Links
Biological Product Shows Promise Against Gum Disease
Date:4/4/2009

When tested in rabbits, resolvins reduced inflammation ,,,,

SATURDAY, April 4 (HealthDay News) -- Resolvins, a new family of biologically active products of omega-3 fatty acids, may be able to remedy the inflammation of periodontal disease and restore gums to health, say Boston University researchers.

Two types of resolvins are made from the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which keep blood triglycerides under control and may inhibit the progression of atherosclerosis. EPA and DHA help reduce inflammation and are often used to help people with inflammatory conditions such as rheumatoid arthritis and Crohn's disease, according to background information in a new release from the International & American Association for Dental Research.

Resolvins of the E series (RvE1) are derived from EPA, and resolvins of the D series (RvD1) are derived from DHA. Previous research showed that RvE1 provided protection against soft tissue and bone loss associated with gum disease and actually restored lost soft tissue and bone to healthy levels.

In this new study, the researchers caused gum disease in rabbits by applying P. gingivalis, the bacteria that causes gum disease in humans. Treatment with RvD1 was beneficial.

The study was to be presented Saturday at the research association's meeting in Miami.

The finding supports the researchers' hypothesis that DHA-derived resolvins, as well as those derived from EPA, have the potential to resolve inflammation and restore periodontal health, the association said in its news release.

More information

The American Academy of Periodontology has more about gum disease.



-- Robert Preidt



SOURCE: International & American Association for Dental Research, news release, April 4, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Thomson Scientific Announces BONDplus for Biological Researchers
2. Neurobiological Technologies Reports Going Concern Qualification
3. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
4. Study questions assumptions about human sensitivity to biological motion
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
7. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
8. Biological markers of prostate cancer shed light on cancer burden faced by African-American men
9. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
10. Biological Link Between BRCA1 and Breast Cancer Detailed
11. Boston IVF is First in Northeast to Offer Pioneering Test of Womens Biological Clock
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biological Product Shows Promise Against Gum Disease
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
(Date:11/30/2016)... 2016 Research and Markets has announced the ... MedCore" report to their offering. ... , Detachable coil embolization is ... malformations. The detachable coil embolization treatment of cerebral aneurysms is less invasive ... weakened area in the wall of an artery in the brain. This ...
Breaking Medicine Technology: